Evaluation of Effectiveness and Safety of Orsiro in Routine Clinical Practice; A Multicenter, Prospective Observational Study
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 20 Dec 2017
Price : $35 *
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms IRIS-ORSIRO
- 07 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 15 Jun 2016 Planned End Date changed from 1 Jun 2020 to 1 Sep 2021.
- 15 Jun 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Sep 2017.